IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达

黄颖; 刘熠晗; 黎承平; 武坤; 曾云

IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达

昆明医科大学第一附属医院血液科

基金项目:

基金：云南省教育厅科学研究基金资助项目 (2013Y292);

计量
- 文章访问数: 2108
- HTML全文浏览量: 769
- PDF下载量: 30
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-03

The Expression and Significance of IL-17 and IL-23 in Patients with B-cell non-Hodgkin Lymphoma Treated by RCHOP

Funds:

基金：云南省教育厅科学研究基金资助项目 (2013Y292);

摘要

摘要: 目的检测B细胞非霍奇金淋巴瘤 (non-Hodgkin lymphoma, NHL) 患者治疗前后IL-17、IL-23表达水平的变化, 探讨IL-17、IL-23在NHL发生发展过程中的作用.方法应用逆转录-聚合酶链式反应 (reverse transcription-polymerase chain reaction, RT-PCR) 法检测25例接受标准剂量R-CHOP方治疗68个疗程的B细胞NHL患者和20例健康对照组.结果 NHL患者初诊时和缓解时外周血中IL-17m RNA的表达水平均低于健康对照组 (P<0.05) .NHL患者缓解时与初诊时相比, IL-17m RNA的表达水平有所升高 (P<0.05) .NHL患者初诊时和缓解时外周血中IL-23m RNA的表达水平均低于健康对照组 (P<0.05) .缓解时与初诊时相比, IL-23m RNA的表达水平升高 (P<0.05) .结论 B细胞非霍奇金淋巴瘤患者接受利妥昔单抗治疗后IL-17、IL-23水平升高.IL-17、IL-23m RNA的表达与预后相关.
- 非霍奇金淋巴瘤 /
- 白介素-17 /
- 白介素-23 /
- 利妥昔单抗 /
- 预后
Abstract: Objectives To detect the expression levels of IL-17 and IL-23 in peripheral blood of B-cell non-Hodgkin lymphoma patients treated by RCHOP and to study the role of IL-17 and IL-23 in NHL.Methods Twenty-five patients with B-cell NHL who achieved remission after 6 to 8 cycles of R-CHOP as a NHL group, 20 healthy volunteers were recruited as a normal control group.RT-PCR was used to detect the expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients and health volunteers.Results The expression levels of IL-17 m RNA and IL-23 m RNA in the patients with NHL before therapy and the patients with NHL who achieved remission were lower than that in the normal control group (P<0.05) .The expression levels of IL-17 m RNA and IL-23 m RNA in the patients with NHL who achieved remission were higher than that in the patients with NHL before therapy (P=0.001, P<0.05) .Conclusions IL-17 and IL-23 m RNA levels are higher after treated with R-CHOP. The expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients are related with prognosis and efficacy.
- Non-Hodgkin lymphoma /
- Interleukin-17 /
- Interleukin-23 /
- Rituximab /
- Prognosis

HTML全文

参考文献(13)

[1]	[1]SIEGEL R L, MILLER K D, JEMAL A.Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65 (1) :5-29.
[2]	[2]STASICR, DELPOETAG, STIPAE, et al.Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura[J].Blood, 2007, 110 (8) :2924-2930.
[3]	[3]STASI R, COOPERN, DELPOETAG, et al.Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab[J].Blood, 2008, 112 (4) :1147-1150.
[4]	[4]SHAHRARAS, HUANGQ, MANDELINAM, et al.TH-17 cells in rheumatoid arthritis[J].Arthritis Res Ther, 2008, 10 (4) :R93.
[5]	[5]RACKEMK.Immunopathogenesis of multiple sclerosis[J].Ann Indian Acad Neurol, 2009, 12 (4) :215-220.
[6]	[6]ZHOU L, LITTMANDR.Transcriptional regulatory networks in Th17 cell differentiation[J].Curr Opin Immunol, 2009, 21 (2) :146-152.
[7]	[7]STARK M A, HUO Y, BURCIN T L, et al.Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17[J].Immunity, 2005, 22 (3) :285-294.
[8]	[8]TZANKOVA, MEIERC, HIRSCHMANNP, et al.Correlation of high numbers of intratumoral FOXP3+regulatory T cells with improved survival in germinal center like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma[J].Haematologica, 2008, 93 (2) :193-200.
[9]	[9]GHILARDIN, OUYANGW.Targeting the development and effector functions of TH17 cells[J].Semin Immunol, 2007, 19 (6) :383-393.
[10]	[10]SAKAGUCHI S.Regulatory T cells:Key controllers of immunologic self-tolerance[J].Cell, 2000, 101 (5) :455-458.
[11]	[11]PARK H, LIZ, YANGXO, et al.A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17[J].Nat Immunol, 2005, 6 (11) :1133-1141.
[12]	[12]OPPMANNB, LESLEYR, BLOMB, et al.Novel p19 protein engages IL-12p40 to form a cytokine from a cytokine, IL-23, with biological activities similar as well as distinct from IL-12[J].Immunity, 2000, 13 (5) :715-725.
[13]	[13]LU T, YUS, LIUY, et al.Aberrant circulating Th17 cells in patients with B-cell non-hodgkin’s lymphoma[J].PLo S One, 2016, 11 (1) :e0148044.

相关文章(20)

[1]	门欣怡, 赵静, 申永椿, 季辉, 王秀霞. 外周血免疫球蛋白、血沉、同型半胱氨酸与儿童中枢神经系统血管炎病情程度的关系及对预后的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241217
[2]	刘兴许, 李梅华, 任朝凤, 王蔚平, 李丽, 柏媛, 张春梅, 蒋菁, 郑章敏, 周冬玉. KL-6、IL-17与CTD-ILD的相关性研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241017
[3]	刘春艳, 常炳庆, 李超, 任欣, 刘小琴. T淋巴细胞亚群与急性髓系白血病病理特征的关系及预测化疗预后的价值分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240518
[4]	聂琪, 刘莉, 田玥, 毛晓燕, 郭渠莲, 田新. 儿童急性B淋巴细胞白血病ACTH异常临床特征与预后分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241012
[5]	唐嘉黛, 杨静, 宋红莉, 陈娇娇, 缪忠惠, 谢琳. 318例原发性胃癌转移及预后影响因素的相关分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230218
[6]	高婷, 黄胜, 郭瑢, 陈德滇. 乳腺粘液腺癌的临床病理特征及预后分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230306
[7]	陆小华, 袁洪新. BTLA、CTLA-4基因多态性与肝癌TACE联合靶向治疗疗效及预后相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230927
[8]	张霞, 聂文莎, 王惠萍, 王左华, 王春霞, 郑宇霞. 利妥昔单抗联合甲强龙治疗自身免疫性脑炎的疗效及对外周血PD-1、PD-L1的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230428
[9]	胡昌猛, 吴琳. Silva分型与宫颈HPV相关腺癌预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220817
[10]	田波, 沈银忠, 白劲松, 刘俊, 陈海云, 孙建军. 艾滋病患者中播散性马尔尼菲篮状菌病与播散性非结核分枝杆菌病的临床特征, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220718
[11]	李诗洲, 何晓光, 林雁, 李玉晓, 杨曦, 王晓雨, 杨声豪. 原发灶不明颈部淋巴结转移鳞状细胞癌的临床分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220710
[12]	陈红兰, 吴怡, 胡滔, 王玉明. 外周血G6PD活性检测对于感染高危型人乳头瘤病毒宫颈癌患者的诊断预后价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220203
[13]	苏建培, 田伟盟, 顾俊, 何弥玉. C反应蛋白/白蛋白比值与老年心力衰竭患者长期预后的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201236
[14]	张爱灵. 常规分割与大分割三维适形放射治疗非小细胞肺癌合并上腔静脉压迫综合征, 昆明医科大学学报.
[15]	聂波. 结外NK/T细胞淋巴瘤鼻型34例临床分析, 昆明医科大学学报.
[16]	黄颖, 刘熠晗, 黎承平, 武坤, 曾云. IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达, 昆明医科大学学报.
[17]	刘巨鹏. 陈旧心肌梗死患者胱抑素C水平及预后相关性研究, 昆明医科大学学报.
[18]	杨婧. 原发性胆汁性肝硬化外周血及肝组织中Th17/IL-17轴的初步研究, 昆明医科大学学报.
[19]	石磊. 31例脑胶质瘤临床预后及其影响因素分析, 昆明医科大学学报.
[20]	刘健刚. 趋化因子受体CXCR4在颅咽管瘤中的表达及其与预后的关系, 昆明医科大学学报.